AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosing of First Participant in Second Cohort


Research Triangle Park, N.C., March 07, 2025 (GLOBE NEWSWIRE) --
  • Data Safety Monitoring Board (DSMB) recommendation to initiate second cohort follows review of Phase 1/Phase 2 LION-CS101 trial safety data for AB-1003
  • Second cohort enrollment is ongoing

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the advancement of the Phase 1/Phase 2 LION-CS101 clinical trial of investigational gene therapy AB-1003 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) with dosing of the first participant in the second cohort. The recommendation to advance to the second cohort followed the completion of a Data Safety Monitoring Board (DSMB) review of trial recruitment activity, and safety reporting from the first cohort that determined it was safe to proceed to cohort two. DSMBs are independent groups of experts appointed to periodically review information from clinical trials. These reviews typically include risk-benefit assessments and monitoring for serious or unexpected adverse safety events alongside any significant benefit of therapies.1

The LION-CS101 clinical trial is a double-blind, randomized, placebo-controlled, dose-escalation clinical trial to evaluate the safety of AB-1003 gene therapy in adult participants (18–65 years) who have genetic confirmation of LGMD2I/R9. The trial includes two sequential, dose-level cohorts. Adult participants diagnosed with LGMD2I/R9 will be given a single intravenous infusion of AB-1003 or placebo.

The trial was initiated in 2023. It will include up to 14 participants at six sites throughout the United States.2 Participants in the first cohort remain in the study until completion. Enrollment in cohort two is ongoing. For more information about the LION-CS101 clinical trial, visit clinicaltrials.gov (NCT05230459) or askbio.com.

“The burden of LGMD2I/R9 on patients and their families is profound,” said Nicholas Johnson, MD, Principal Investigator and Vice Chair of Research at the Department of Neurology, Virginia Commonwealth University School of Medicine. “Dosing the first participant in the second cohort of the trial is positive news for people living with LGMD2I/R9. This is a rare and debilitating type of muscular dystrophy, and this advancement brings the LION-CS101 trial another step closer to completion.”

AskBio has received rare pediatric disease designation (RPDD), orphan-drug designation (ODD) and fast track designation (FTD) for AB-1003 for the potential treatment of LGMD2I/R9 from the United States Food and Drug Administration (FDA).3-4 These designations serve as clear recognition of the significant unmet medical need in LGMD2I/R9, for which there is no approved therapy.5

“The dosing of the first participant in cohort two marks an important milestone for the trial as enrollment continues for LION-CS101,” said Canwen Jiang, MD, PhD, Chief Development Officer and Chief Medical Officer, AskBio. “We are encouraged by the DSMB’s recommendation to advance our study, following their thorough assessment of AB-1003 in cohort one and are excited to proceed with the second cohort.”  

AB-1003 is an investigational recombinant adeno-associative virus (AAV)-based gene therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been fully established or evaluated. It is designed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9 as a one-time intravenous (IV) infusion.2-4

About Limb-Girdle Muscular Dystrophy Type 2I/R9

LGMD2I/R9 is a rare form of LGMD caused by mutations in the FKRP gene and is associated with weakness and wasting of arm and leg muscles.6 Those with LGMD2I/R9 notice symptoms in late childhood, typically around 11 years of age, and may experience difficulty running and walking. The symptoms gradually worsen over time, and affected people generally rely on wheelchairs for mobility and may experience impaired heart and lung function.5-7 LGMD2I/R9 is estimated to affect fewer than 5,000 people in the United States.6 Currently, there is no approved treatment, and management is based on the signs and symptoms present in each individual.5

About AskBio 

AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular, and metabolic disease indications with a clinical-stage pipeline that includes investigational therapeutics for congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive array of capsids and promoters. With global headquarters in Research Triangle Park, North Carolina, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing. An early innovator in the gene therapy field, with over 900 employees in five countries, the company holds more than 600 patents and patent applications in areas such as AAV production and chimeric capsids. Learn more at www.askbio.com or follow us on LinkedIn. 

About Bayer 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

AskBio Forward-Looking Statements

This press release contains “forward-looking statements.” Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding AskBio’s clinical trials. These forward-looking statements involve risks and uncertainties, many of which are beyond AskBio’s control. Known risks include, among others: AskBio may not be able to execute on its business plans and goals, including meeting its expected or planned clinical and regulatory milestones and timelines, its reliance on third-parties, clinical development plans, manufacturing processes and plans, and bringing its product candidates to market, due to a variety of reasons, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our third-party collaborators and partners, and regulatory, court or agency feedback or decisions, such as feedback and decisions from the United States Food and Drug Administration or the United States Patent and Trademark Office. Any of the foregoing risks could materially and adversely affect AskBio’s business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. AskBio does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof

References

[1] Van Norman GA. Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials. JACC Basic Transl Sci. 2021;6(11):887-896. 

[2] AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Available at: https://www.askbio.com/askbio-announces-first-patient-dosed-in-phase-1-phase-2-lgmd2i-r9/. Accessed March 2025.

[3] AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9. Available at: https://www.askbio.com/askbio-receives-fda-rare-pediatric-disease-and-orphan-drug-designations-for-ab-1003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9/. Accessed March 2025.

[4] AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Available at: https://www.askbio.com/askbio-receives-fda-fast-track-designation-for-lion-101-a-novel-investigational-aav-gene-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9-lgmd2i-r9/. Accessed March 2025.

[5] Limb-Girdle Muscular Dystrophy (LGMD). Available at: https://my.clevelandclinic.org/health/diseases/limb-girdle-muscular-dystrophy-lgmd. Accessed March 2025.

[6] NIH – Autosomal recessive limb-girdle muscular dystrophy type 2i. Available at: https://rarediseases.info.nih.gov/diseases/12536/autosomal-recessive-limb-girdle-muscular-dystrophy-type-2l.  Accessed March 2025.

[7] Willis E, Moore SA, Cox MO, Stefans V, Aravindhan A, Gokden M, Veerapandiyan A. Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in FKRP Gene. Child Neurol Open. 2022 Apr 28;9.


AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosing of First Participant in Second Cohort

Phil McNamara Asklepios BioPharmaceutical, Inc. (AskBio) +1 (984) 5207211 pmcnamara@askbio.com

THỦ THUẬT HAY

Hướng dẫn ẩn ảnh trên iPhone một cách nhanh chóng và an toàn

Trong bài viết này, chúng ta hoàn toàn có thể tận dụng cách này để cất giữ ảnh một cách an toàn mà không sợ bị người khác xem được. Bạn hoàn toàn có thể khóa bằng mật khẩu riêng hoặc bằng Touch ID. Các bạn hãy làm theo

2 cách cập nhật chứng nhận tiêm vaccine Covid-19 nhanh nhất cho bạn

Nếu chứng nhận tiêm chủng vaccine Covid-19 bị sót, chưa cập nhật đầy đủ, thì có thể phản ánh lên nền tảng quản lý tiêm chủng bằng cách cập nhật chứng nhận tiêm vaccine Covid-19 này...

iOS 7 chặn cuộc gọi, tin nhắn từ số chỉ định

Đáp ứng mong mỏi từ lâu của các tín đồ của 'Quả táo', Apple đã cung cấp thêm tính năng chặn cuộc gọi cho iOS 7. Ngoài việc chặn cuộc gọi, tính năng này còn chặn cả tin nhắn văn bản và cuộc gọi FaceTime của số điện

Muốn giỏi tiếng Anh, đừng quên ghé thăm 13 kênh YouTube này mỗi ngày

Ngoài phim ảnh thì YouTube cũng là một kho tài nguyên mà bất cứ người học tiếng Anh nào cũng không thể bỏ qua. Nếu chỉ nghĩ đến những video hài hước, quảng cáo, phim tài liệu hay các video ca nhạc đủ mọi thể loại thì

Top các công cụ xóa chữ trong ảnh miễn phí hiệu quả nhất

Bạn muốn làm đơn giản và đẹp cho bức ảnh của mình. Chẳng hạn chỉnh sửa những chi tiết như câu từ, ngày tháng hay bất kỳ đối tượng nào khác. Giờ đây, có rất nhiều phần mềm xóa chữ trên ảnh miễn phí mà hiệu quả. Hãy cùng

ĐÁNH GIÁ NHANH

Đánh giá Surface Go: Thiết kế ấn tượng, hiệu năng đủ dùng

Surface Go là chiếc máy tính bảng nhỏ nhất và rẻ nhất của Microsoft, tuy nhiên thông số kỹ thuật và các ứng dụng vẫn có thể khiến người dùng khó tính cảm thấy hài lòng. Surface Go không phải là một chiếc tablet để đối

Trên tay LG V30: màn hình OLED đẹp, không rỗ, thiết kế hoàn thiện như Samsung

LG V30 có màn hình OLED đẹp, màu sắc rực rỡ, không rỗ và ít ám màu. So với màn hình Amoled (cũng là một dạng OLED) hiện nay trên thị trường thì khả năng hiển thị vượt trội hơn.

Đánh giá Archos 80c Xenon: Vô địch trong tầm giá

Archos 80c Xenon là chiếc máy tính bảng giá rẻ có thiết kế cứng cáp, màn hình lớn và thời lượng pin vượt trội, mang đến những trải nghiệm tốt nhất trong tầm giá